Skip to content 
Pure Lab Peptides created this guide for research buyers who want to buy BPC-157 for research while keeping procurement, documentation, and literature review strictly research-use-only. BPC-157 is discussed here as a research peptide with compound-identity, purity, COA, and analytical-testing considerations, not as a consumer product. Published literature can help define research context, but it should not be converted into product-use claims.
- BPC-157 is commonly described in databases and literature as a synthetic pentadecapeptide associated with the molecular formula C62H98N16O22 and PubChem CID 9941957 [1].
- The sequence GEPPPGKPADDAGLV and approximate molecular weight near 1419 Da appear in published BPC 157 literature [2].
- Literature on BPC-157 research includes model-specific work involving tendon fibroblast behavior, angiogenesis, nitric oxide signaling, endothelial context, and FAK-paxillin pathway discussion [4] [6] [9].
- HPLC and LC-MS records serve different documentation roles: HPLC can support peptide purity review, while mass spectrometry can help support peptide identity review when paired with appropriate reference data and batch records [12] [13].
- Researchers should compare compound name, lot number, COA date, analytical methods, purity data, identity records, label consistency, and storage documentation before procurement.
Fast Answer: What Should Researchers Check Before They Buy BPC-157 for Research?
Researchers evaluating where to buy BPC-157 for research should first review RUO labeling, batch-specific COA documentation, peptide purity data, LC-MS or equivalent identity support, lot traceability, and supplier documentation consistency. Products discussed in this article are intended for laboratory research use only and are not intended for human or animal consumption. Literature should be read as model-specific research context, not product guidance.
Which Product Documentation Should Come First?
The first documents to review are the product label, COA, lot identifier, analytical method notes, and storage documentation. These records should describe the same material in the same way.
A COA should not stand alone if the label, product page, and batch record conflict. For a research peptide, consistency across documents is a core procurement signal.
Why Does RUO Labeling Matter Before Procurement?
RUO labeling clarifies that the material is positioned for laboratory research, not consumer or clinical contexts. FDA guidance for RUO-labeled in vitro diagnostic products explains that RUO labeling is meant to identify materials in a laboratory research phase and distinguish them from diagnostic contexts [16].
Research-Use-Only Context for BPC-157
This article does not provide personal-use, clinical-use, cosmetic-use, fitness-use, or product-performance guidance.
How Documentation Keeps BPC-157 Research Separate From Product Claims
Published studies describe experimental models. They do not establish the identity, purity, or suitability of a supplier’s material; those questions require review of the specific product documentation.
FDA’s current compounding-safety page notes concerns for BPC-157 involving peptide-related impurities and active pharmaceutical ingredient characterization in the compounding context [17]. For research procurement, that reinforces why characterization records matter.
What Is BPC-157 in Synthetic Peptide Literature?
BPC-157 is commonly described as a synthetic peptide and pentadecapeptide. PubChem lists BPC-157 under CID 9941957 with the molecular formula C62H98N16O22 [1].
Published BPC 157 literature also describes the sequence GEPPPGKPADDAGLV and a molecular weight near 1419 Da [2]. Those identity markers are useful for checking whether a product listing, label, and COA refer to the same target compound.
Compound Identity and 15-Amino Acid Peptide Classification
“Pentadecapeptide” means a peptide composed of 15 amino acids. For BPC-157, published literature identifies the sequence as GEPPPGKPADDAGLV [2].
The phrase “BPC” is often expanded in literature as body protection compound, but this page treats that phrase only as nomenclature. It is not used here as a product claim.
Why Does Pentadecapeptide BPC 157 Naming Matter?
Naming matters because BPC-157 appears in literature as BPC 157, pentadecapeptide BPC 157, gastric pentadecapeptide, and stable gastric pentadecapeptide BPC 157. Those variants should point back to the same canonical compound record unless a document specifies a different salt, form, or listing.
Researchers should also distinguish the parent compound from acetate-associated records. PubChem lists a separate BPC-157 acetate record associated with the parent compound, which can alter formula and mass context in documentation review [19].
How Stable Gastric Pentadecapeptide BPC 157 Is Described in Research
Published reviews describe stable gastric pentadecapeptide BPC 157 in relation to gastric-juice-derived research context and cytoprotection literature [2] [3]. That background explains the gastric pentadecapeptide classification used in the research literature.
The term helps identify the compound in literature; it should not become a product-positioning claim.
How Does Published Literature Frame BPC-157 Research?
Published literature frames BPC-157 research largely through preclinical and in vitro models. Several papers discuss tendon fibroblast models, angiogenesis-related models, vascular signaling, nitric oxide, and endothelial pathways [4] [6] [8] [9].
That literature is useful for topical context. It is not a substitute for product documentation, and it should not be used as product-use guidance.
What Preclinical and In Vitro Models Can Show?
Preclinical and in vitro models can show how a compound behaves in a controlled research setting. For example, a tendon fibroblast model study reported changes in tendon fibroblast outgrowth, cell survival under stress conditions, and cell migration, with discussion of FAK-paxillin pathway involvement [4].
Model data can support research hypotheses. It cannot establish product claims for RUO materials.
Where Literature Interpretation Requires Caution
BPC-157 research literature includes many model-specific findings, but evidence levels are not the same across study types. A recent evidence review emphasized that much of the available BPC-157 literature remains preclinical or early-stage and requires careful interpretation [11].
Cellular Pathway Context for BPC 157 Research
Researchers have examined BPC 157 in relation to angiogenic signaling, VEGF-related markers, and vascular model systems [6] [7] [8]. These model-specific findings do not establish the properties of a supplier’s product.
How Angiogenesis Appears in Research Models?
Angiogenesis refers to the formation of new blood vessels in biological research. BPC 157 literature has discussed angiogenesis and angiogenic growth factors in experimental model systems, including VEGF-related context [6] [7] [8].
How Nitric Oxide, Endothelial, and FAK-Paxillin Contexts Fit?
Nitric oxide and endothelial signaling appear in BPC 157 research as pathway-context terms. A Scientific Reports study evaluated BPC 157 in isolated aorta and discussed nitric oxide-related signaling through Src-Caveolin-1-eNOS context [9].
FAK-paxillin appears in tendon fibroblast literature as a pathway associated with cell migration in a model system [4]. This mechanistic context does not establish the properties of a supplier’s research material.
Gastric Pentadecapeptide BPC 157 Terminology
The phrase “gastric pentadecapeptide” appears because BPC 157 literature connects the compound to gastric-juice-derived peptide research and stomach cytoprotection concepts [2] [3]. That terminology helps connect database identity, historical naming, and literature retrieval.
What Does Gastric Pentadecapeptide Mean in Research?
“Gastric pentadecapeptide” is a descriptive research term. It points to a 15-amino acid peptide discussed in gastric research literature, including the GEPPPGKPADDAGLV sequence [2].
This terminology can help research teams locate relevant papers. It does not change the research-only status of the material.
How Do Tendon Fibroblast Models Fit Literature Context?
Tendon fibroblast models appear in BPC-157 research because fibroblasts are useful for studying cell migration, cell survival, cell growth, and pathway signaling in controlled systems. The 2011 Journal of Applied Physiology paper connected BPC 157 model findings with tendon fibroblast outgrowth, migration, and FAK-paxillin signaling [4].
A later Molecules paper evaluated growth hormone receptor expression in tendon fibroblasts as a model readout [5]. These findings remain research-context findings.
Evidence Interpretation Framework for BPC-157 Peptide Research
A safer way to read BPC-157 literature is to sort evidence by type. Database records identify the compound; analytical records support material review; in vitro studies explore cellular behavior; preclinical literature explores model-specific outcomes; reviews summarize patterns and limitations.
| Research Area | What Literature Examines | Evidence Type | RUO Interpretation |
|---|---|---|---|
| Compound identity | Formula, sequence, naming, and parent-compound records [1] [2] | Database and literature record | Useful for label, COA, and identity review |
| Tendon fibroblast models | Cell migration, cell survival, and FAK-paxillin signaling context [4] | In vitro model | Research pathway context only |
| Angiogenesis context | VEGF-related and angiogenic-growth-factor discussion [6] [7] [8] | Model studies and review | Pathway relevance, not product positioning |
| Nitric oxide context | Endothelial and eNOS-related signaling in controlled models [9] | Mechanistic model | Literature context only |
| Analytical documentation | HPLC, chromatograms, specificity, selectivity, and orthogonal methods [12] [13] | Analytical chemistry guidance | Supports documentation review |
How Should Lab Teams Read Mechanistic Findings?
Lab teams should ask what model was studied, what endpoint was measured, and what the study can actually support. A tendon fibroblast finding, for example, belongs to a tendon fibroblast model.
This approach keeps BPC-157 research specific. It avoids turning pathway relevance into a broad product claim.
What Can Research Reviews Contribute?
A review can summarize patterns across BPC-157 studies [10] [11].
Why Is Pathway Relevance Not a Product Claim?
A pathway term is not a product claim by itself. Angiogenesis, nitric oxide, endothelial signaling, vascular endothelial growth factor, and FAK-paxillin can all be research terms when tied to model-specific literature [4] [6] [9].
Interpret those terms in relation to the model, methods, and endpoints of the cited study.
Important distinctions for research buyers:
- Published literature does not equal product-page guidance.
- Preclinical findings should not be converted into broad claims.
- A purity percentage does not prove complete peptide identity.
- A COA should be batch-specific whenever possible.
- Pathway relevance does not equal a product claim.
- Catalog amounts are listing specifications, not research parameters.
Why COA Documentation Matters for BPC-157 Research Materials?
A certificate of analysis is one of the most important product-page records for a research peptide. It should connect the listed compound with batch-specific data.
For BPC-157, useful COA review focuses on identity, purity, analytical method, lot number, COA date, and supplier documentation. ICH Q2(R2) states that analytical procedures should be evaluated for characteristics such as specificity, selectivity, range, accuracy, precision, and robustness where applicable [13].
What Certificate of Analysis Details Should Researchers Review?
Researchers should look for a lot number, compound name, testing date, purity result, method name, chromatogram reference, and identity-support note. When an analytical procedure is used for identity or purity review, the method should be fit for its intended purpose [13] [14].
A COA that only lists a general purity percentage is less informative than one that links the result to a batch and method.
How Batch-Specific Documentation Supports Research Procurement
Batch-specific documentation lets research teams connect a product listing to a defined lot. That connection is central to traceability.
A useful review asks whether the product page, label, COA, and supplier records identify the same BPC-157 material. If they do not, procurement teams should resolve the mismatch before selection.
Where Third-Party Tested Documentation Fits
Third-party tested documentation can add confidence when the method, lab, date, and lot relationship are clear. The key is transparency.
Third-party testing should not be treated as a slogan. It should be supported by records that researchers can review.
How Should Researchers Review Peptide Purity for BPC-157?
Peptide purity review should focus on the analytical method and the document trail. HPLC is commonly used for peptide separation and purification workflows, including reversed-phase approaches for peptide analysis [12].
A purity percentage is useful only when the method context is visible. Researchers should look for chromatogram data, peak labeling where available, and lot-level connection.
How HPLC Supports Peptide Purity Review?
HPLC can help separate peptide-related components and support purity review through chromatographic data [12]. ICH Q2(R2) also notes that representative data such as chromatograms can help demonstrate specificity for assay, purity, or impurity tests [13].
For BPC-157 research procurement, the practical question is whether the HPLC record is linked to the batch being evaluated.
What Chromatogram Details Help Researchers Evaluate Purity?
Useful chromatogram details can include retention time, peak shape, peak area reporting, method conditions, and clear connection to the sample record. ICH Q2(R2) emphasizes that representative analytical data should identify relevant components where appropriate [13].
Chromatogram review does not replace identity testing. It supports one part of the documentation package.
LC-MS Identity Verification and Mass Spectrometry Review
LC-MS combines liquid chromatography with mass spectrometry, making it useful for identity-oriented analytical review. In peptide work, mass spectrometry can help evaluate mass-to-charge information and support peptide identification when paired with suitable reference data [15].
For BPC-157, LC-MS should be treated as part of a documentation workflow. It is strongest when paired with batch records, sequence expectations, and COA consistency.
How LC-MS Supports Peptide Identity Confirmation?
LC-MS can support peptide identity confirmation by comparing mass-related signals with expected compound information. FDA’s ICH M10 guidance discusses validation elements for chromatographic methods, including selectivity, specificity, accuracy, precision, carryover, stability, and related performance elements [15].
Published analytical literature has also used mass-spectrometry workflows to identify BPC 157 and related signals in controlled laboratory analysis [18].
Why Molecular Weight and Sequence Data Matter
Molecular weight and sequence data help connect the product listing to the expected compound identity. For BPC-157, the GEPPPGKPADDAGLV sequence and approximate 1419 Da molecular weight are useful cross-checks against literature and database records [2].
Sequence and mass data are reference points for documentation review.
Lot Traceability and Supplier Documentation Review
Lot traceability connects a research material to a specific batch record. Without that connection, a COA may not prove that the listed material and tested material are the same.
For product-page review, traceability is practical. It helps research teams compare the product page, label, COA, and storage notes.
Why Should Research Buyers Review Lot Traceability?
Research buyers should review lot traceability because analytical records are most useful when they map to the material being evaluated. A lot number should appear consistently across the COA and supplier documentation.
If a supplier updates a COA or product listing, the lot relationship should remain clear. That prevents documentation drift.
How Label Consistency Supports Research Material Review
Label consistency supports material review by showing that product name, lot number, and research-use-only status align. It also helps prevent confusion between BPC-157, BPC 157, pentadecapeptide BPC 157, and any salt-specific listing.
For procurement teams, the label and COA should tell the same story.
Storage and Handling Documentation for Research Materials
Storage documentation should describe how the material is intended to be maintained in a laboratory inventory system.
For peptide research materials, storage records can support chain-of-custody review, inventory control, and documentation consistency. They also help research teams preserve the integrity of their internal records.
What Storage Records Should Accompany Lab-Grade Peptides?
Storage records may include stated storage condition, lot number, product name, COA date, receipt date, and internal inventory notes. ICH Q14 emphasizes analytical procedure development and lifecycle knowledge management for quality-related assessments [14].
For a product-page reader, the key is whether storage notes align with the label and documentation. Mixed or unclear records should be clarified before procurement.
Research Procurement Checklist Before Researchers Buy BPC-157 for Research
Before researchers buy BPC-157 for research, the review should be documentation-first. A strong procurement workflow checks the product page, COA, purity record, identity support, lot traceability, and RUO label.
Quality and documentation checklist:
- Verify that the product page identifies BPC-157 as a research-use-only material.
- Review the batch-specific certificate of analysis.
- Confirm that peptide purity data are tied to an analytical method.
- Check that the lot number matches across supplier documentation.
- Compare compound name, molecular weight, sequence, and salt-form notes where available.
- Assess whether the page avoids consumer, clinical-use, and product-performance claims.
- Document storage and handling conditions in a laboratory record.
Laboratory documentation verification workflow:
- Verify the compound name, lot number, and label match across product documents.
- Review the batch-specific COA.
- Check whether the peptide purity method is listed.
- Confirm whether identity support includes LC-MS or another suitable analytical method.
- Review chromatogram or mass data when available.
- Check the COA date and testing source.
- Record storage and handling details in the laboratory documentation file.
What Records Matter Before Teams Buy BPC-157 for Research?
The most useful records are the product label, batch-specific COA, HPLC purity documentation, LC-MS identity support, lot traceability, storage notes, and supplier documentation. Analytical guidance such as ICH Q2(R2) and ICH Q14 supports the broader principle that methods should be fit for purpose and properly documented [13] [14].
Research-Only Scope at Pure Lab Peptides
Pure Lab Peptides supplies compounds for laboratory research use only. Products are not intended for human or animal consumption, diagnostic use, therapeutic use, clinical use, veterinary use, or as food, drugs, cosmetics, dietary supplements, or household products. Researchers are responsible for ensuring lawful, appropriate handling and use in accordance with applicable regulations and institutional guidelines.
Review the product-page documentation, COA details, and RUO labeling before evaluating this compound for laboratory research.
FAQs
What is BPC-157 peptide in research literature?
BPC-157 peptide is described in research literature as a synthetic 15-amino-acid research peptide. Published records associate BPC-157 with the peptide sequence GEPPPGKPADDAGLV and a defined molecular formula, which can support compound characterization and documentation review [1] [2]. On an RUO product page, those details help researchers compare label, COA, and identity records.
What is gastric pentadecapeptide BPC 157?
Gastric pentadecapeptide BPC 157 is a research-literature naming variant for BPC-157. The term reflects literature context connected to gastric peptide research, including descriptions of a synthetic peptide derived from a naturally occurring sequence discussed in gastric-juice-related research [2].
What should researchers consider before they buy BPC-157 for research?
Researchers should consider documentation before they buy BPC-157 for research. Key review points include RUO labeling, batch-specific COA records, lot traceability, peptide purity data, peptide identity support, and supplier documentation consistency. The goal is to confirm that product records describe the same research material across the label, COA, and analytical documentation.
How should BPC-157 literature be interpreted for RUO materials?
BPC-157 literature should be interpreted as research context, not product-use guidance. In vitro and preclinical literature may discuss cell proliferation, pathway models, or experimental endpoints, but those findings should stay tied to the model being studied.
What storage documentation should accompany BPC-157 research materials?
Storage documentation should accompany BPC-157 research materials as part of the laboratory record. Useful records may include product name, lot number, COA date, storage condition, receipt date, and internal inventory notes. This documentation helps technical teams maintain a consistent chain of product records.
How does chromatogram review support BPC-157 documentation?
Chromatogram review supports BPC-157 documentation by helping researchers evaluate peptide purity records in connection with a batch-specific COA. HPLC chromatograms can provide method-linked purity information, while LC-MS records may support peptide identity review when paired with suitable reference data [13] [15]. These records are documentation tools, not product claims.
Researchers Cited in This Guide
The researchers listed below are cited for relevant published work. Their inclusion does not imply that they wrote, reviewed, or endorsed this guide or Pure Lab Peptides products.
Predrag Sikiric
Author profile: ORCID
Predrag Sikiric’s cited publications discuss stable gastric pentadecapeptide BPC 157, gastric cytoprotection, nitric oxide-system literature, and related peptide research. These publications provide scientific background on BPC-157 nomenclature and model-specific pathways; they do not establish the properties of a supplier’s product.
Selected publications:
- A Current Pharmaceutical Design review relevant to stable gastric pentadecapeptide BPC 157 research — Current Pharmaceutical Design, 2011. DOI: 10.2174/138161211796196954. PMID: [21548867]
- A review relevant to BPC 157 cytoprotection and gastric research context — Gut and Liver, 2020. PMID: [31158953]
Wen-Chung Tsai
Author profile: Chang Gung Memorial Hospital
Wen-Chung Tsai’s co-authored BPC-157 publications examine tendon fibroblast outgrowth, cell survival, cell migration, and receptor expression. These in vitro studies provide model-specific research context, not evidence of commercial product performance.
Selected publications:
- A peer-reviewed tendon fibroblast model study relevant to BPC-157 research — Journal of Applied Physiology, 2011. DOI: 10.1152/japplphysiol.00945.2010. PMID: [21030672]
- A peer-reviewed receptor-expression study in tendon fibroblast BPC-157 research — Molecules, 2014. DOI: 10.3390/molecules191119066. PMID: [25415472]
REFERENCES
- National Center for Biotechnology Information. BPC-157 compound record. PubChem. Accessed 2026.
- Sikiric P, et al. Stable gastric pentadecapeptide BPC 157 review record. PubMed / Current Pharmaceutical Design. 2011. PMID: 21548867.
- Sikiric P, et al. Stable gastric pentadecapeptide BPC 157 and gastric cytoprotection review. PMC / Current Pharmaceutical Design. 2020.
- Chang CH, Tsai WC, Hsu YH, Pang JHS. Pentadecapeptide BPC 157 tendon-fibroblast model study. Journal of Applied Physiology. 2011. DOI: 10.1152/japplphysiol.00945.2010. PMID: 21030672.
- Chang CH, Tsai WC, Hsu YH, Pang JHS. BPC 157 tendon fibroblast receptor-expression model study. Molecules. 2014. DOI: 10.3390/molecules191119066. PMID: 25415472.
- Hsieh MJ, et al. BPC 157 angiogenesis and VEGFR2 model study. Journal of molecular medicine (Berlin, Germany). 2017. PMID: 27847966.
- Brcic L, et al. BPC 157 angiogenesis model-system article. Journal of Physiology and Pharmacology. 2009.
- Seiwerth S, Rucman R, Turkovic B, et al. BPC 157 and angiogenic-growth-factor literature review. Current Pharmaceutical Design. 2018. DOI: 10.2174/1381612824666180712110447. PMID: 29998800.
- Hsieh MJ, et al. BPC 157 nitric-oxide and endothelial signaling model study. Scientific Reports. 2020. PMID: 33051481.
- Józwiak M, et al. BPC 157 mechanism and literature review. Pharmaceuticals. 2025. PMID: 40005999.
- McGuire FP, et al. BPC-157 evidence landscape narrative review. Current Reviews in Musculoskeletal Medicine. 2025.
- Mant CT, Chen Y, Hodges RS. HPLC analysis and purification of peptides. Methods in Molecular Biology. 2007.
- International Council for Harmonisation. Q2(R2) Validation of Analytical Procedures. ICH. 2023.
- International Council for Harmonisation. Q14 Analytical Procedure Development. ICH. 2023.
- U.S. Food and Drug Administration / ICH. M10 Bioanalytical Method Validation and Study Sample Analysis. FDA. 2022.
- U.S. Food and Drug Administration. RUO and IUO labeling guidance for laboratory research products. FDA. 2013; content current 2018.
- U.S. Food and Drug Administration. Compounding safety-risk page including BPC-157 characterization concerns. FDA. Content current 2026.
- Cox HD, Miller GD, Eichner D. BPC 157 analytical detection and in vitro metabolism study. Drug Testing and Analysis. 2017. DOI: 10.1002/dta.2152. PMID: 28035768.
- National Center for Biotechnology Information. BPC-157 acetate compound record. PubChem. Accessed 2026.
Research Disclaimer
This material is supplied strictly for in vitro laboratory research and is not for human or veterinary use. Published studies describe specific experimental materials, models, and methods; they do not establish the safety, efficacy, or suitability of this catalog product for non-research use. Review the original publications and the lot-specific analytical documentation independently.
There are no reviews yet.